Press coverage about Foamix Pharmaceuticals (NASDAQ:FOMX) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Foamix Pharmaceuticals earned a news sentiment score of 0.03 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 45.6058576581265 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of equities analysts have recently commented on FOMX shares. Credit Suisse Group reiterated a “buy” rating and issued a $9.00 price objective on shares of Foamix Pharmaceuticals in a research note on Wednesday, July 19th. HC Wainwright started coverage on Foamix Pharmaceuticals in a research note on Thursday, August 24th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, Zacks Investment Research downgraded Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd.
Foamix Pharmaceuticals (NASDAQ:FOMX) traded up $0.05 during mid-day trading on Monday, reaching $6.23. The company had a trading volume of 27,340 shares, compared to its average volume of 88,492.
Foamix Pharmaceuticals (NASDAQ:FOMX) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.05). Foamix Pharmaceuticals had a negative return on equity of 39.20% and a negative net margin of 823.74%. The firm had revenue of $0.80 million for the quarter, compared to analyst estimates of $1.50 million. During the same period last year, the business earned ($0.27) earnings per share. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. equities research analysts anticipate that Foamix Pharmaceuticals will post -1.34 EPS for the current fiscal year.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.
What are top analysts saying about Foamix Pharmaceuticals Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Foamix Pharmaceuticals Ltd. and related companies.